Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.30 |
| ▸ | TPH1 | P17752 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Histidine SCHEMBL11606906 | 1.00 | SLC7A5 (0.35) | SLC7A5CYP3A4CYP1A2CTSCHTR2C | |
| Histidine SCHEMBL2586203 | 1.00 | SLC7A5 (0.35) | SLC7A5CYP3A4CYP1A2CTSCHTR2C | |
| Histidine SCHEMBL27902238 | 1.00 | SLC7A5 (0.35) | SLC7A5CYP3A4CYP1A2CTSCHTR2C | |
| Histidine SCHEMBL3490081 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL3088582 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL790244 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL1675273 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL790243 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL27466268 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSC | |
| Histidine SCHEMBL16444321 | 0.96 | CYP3A4 (0.32) | SLC7A5CYP3A4CYP1A2CTSCGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111246859-B | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-111246859-A | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-101674842-A | Compositions and methods for treating alzheimer's disease and dementia | PREVENTIVE NUTRIENT COMPANY IN | 2010-03-17 | — | — | CN | claimed |
| WO-2003099322-A2 | IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF | ISIS INNOVATION LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| CN-116803290-A | Meat processing method capable of reducing content of bound heterocyclic amine | 江南大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-111246859-B | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3684332-A1 | VEGFR-FC FUSION PROTEIN FORMULATIONS | Amgen Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111246859-A | Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component | 诺麦塔制药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3502699-A1 | METHODS FOR DIAGNOSING PANCREATIC CANCER | Metanomics Health GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2002064621-A3 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON LLC (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002064621-A3 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON LLC (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| US-20030082740-A1 | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | ATTENUON, LLC | 2003-05-01 | — | — | US | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |